Antisense WT1 transcription parallels sense mRNA and protein expression in fetal kidney and can elevate protein levels in vitro

Journal of Pathology

Volumn 185, Issue 4, 1998, Pages 352-359

  Moorwood, Kim ^a   Charles, Adrian K ^a   Salpekar, Ashreena ^a   Wallace, Jeremy I ^a   Brown, Keith W ^a   Malik, Karim ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antisense RNA; Wilms' tumour; WT1

Indexed keywords

COMPLEMENTARY RNA;

ARTICLE; BLASTEMA; FETUS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLOMERULUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRON; NEPHROBLASTOMA; PODOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 0031816558     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9896(199808)185:4<352::aid-path119>3.0.co;2-%23     Document Type: Article

References (39)

1. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990; 346: 194-197.
2. Coppēs MJ, Campbell CE, Williams BR. The role of WT1 in Wilms' tumorigenesis (Review). FASEB J 1993; 7: 886-895.
3. Hastie ND. The genetics of Wilms' tumour - a case of disrupted development. Annu Rev. Genet 1994; 28: 523-558.
4. Pelletier J, Bruening W, Kashtan CE, et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991; 67: 437-447.
5. Baird PN, Santos A, Groves N, et al. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome. Hum Mol Genet 1992; 1: 301-305.
6. Breslow NE, Beckwith JB. Epidemiological features of Wilms' tumor: results of the National Wilms' Tumour Study. J Natl Cancer Inst 1982; 68: 429-436.
7. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-520.
8. Kreiderg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell 1993; 74: 679-691.
9. Haber DA, Sohn RL, Buckler AJ, et al. Alternative splicing and genomic structure of the Wilms' tumor gene WT1. Proc Natl Acad Sci USA 1991;88: 9618-9622.
10. Madden SL, Cook DM, Morris JF, et al. Transcriptional repression mediated by the WT1 Wilms' tumor gene product. Science 1991; 253: 1550-1553.
11. Wang ZY, Qiu QQ, Enger KT, et al. A second transcriptionally active DNA-binding site for the Wilms' tumor gene product. WT1. Proc Natl Acad Sci USA 1993; 90: 8896-8900.
12. Drummond IA, Madden SL, Rohwer-Nutter P, et al. Repression of the insulin-like growth factor II gene by the Wilms' tumor suppressor WT1. Science 1992; 257: 674-678.
13. Werner H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms' tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms' tumor gene product. Proc Natl Acad Sci USA 1993; 90: 5828-5832.
14. Gashler AL, Bonthron DT, Madden SL, et al. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms' tumor suppressor WT1. Proc Natl Acad Sci USA 1992; 89: 10984-10988.
15. Harrington MA, Konicek B, Song A, et al. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 1993; 268: 21271-21275.
16. Goodyer P, Dehbi M, Torban E, et al. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, WT1. Oncugene 1995; 10: 1125-1129.
17. Malik KT, Poirier V, Ivins S, et al. Autoregulation of the human WT1 gene promoter. FEBS Lett 1994; 349: 75-78.
18. Rupprecht HD, Drummond IA, Madden SL, et al. The Wilms' tumor suppressor gene WT1 is negatively autoregulated. J Biol Chem 1994; 269: 6198-6206.
19. Maheswaran S, Englert C, Bennett P, et al. The WT1 gene product stabilises p53 and inhibits p53 mediated apoptosis. Genes Dev 1995; 9: 2143-2156.
20. Englert C, Hou X, Maheswaran S, et al. WT1 suppressors synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995; 14: 4662-4675.
21. Bickmore WA, Oghene K, Little MH, et al. Modulation of DNA binding specificity by alternative splicing of the Wilms' tumor WT1 gene transcript. Science 1992; 257: 235-237.
22. Larsson SH, Charlieu JP, Miyagawa K, et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995; 81: 391-401.
23. Kennedy D, Ramsdale T, Mattick J, et al. An RNA recognition motif in Wilms' tumor protein (WT1) revealed by structural modelling. Nature Genet 1996; 12: 329-332.
24. Caricasole A, Duarte A, Larsson SH, et al. RNA binding by the Wilms' tumor suppressor zinc finger proteins. Proc Natl Acad Sci USA 1996; 93: 7562-7566.
25. Huang A, Campbell CE, Bonetta L, et al. Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms' tumor. Science 1990; 250: 991-994.
26. Yeger H, Cullinane C, Flenniken A, et al. Coordinate expression of Wilms' tumor genes correlates with Wilms' tumor phenotypes. Cell Growth Differ 1992; 3: 855-864.
27. Campbell CE, Huang A, Gurney AL, et al. Antisense transcripts and protein binding motifs within the Wilms' tumour (WT1) locus. Oncogene 1994; 9: 583-595.
28. Eccles MR, Grubb G, Ogawa O, et al. Cloning of novel Wilms' tumor gene (WT1) cDNAs; evidence for antisense transcription of WT1. Oncogene 1994; 9: 2059-2063.
29. Malik KTA, Wallace JI, Ivins SM, et al. Identification of an antisense WT1 promoter in intron 1 : implications for WT1 gene regulation. Oncogene 1995; 11: 1589-1595.
30. Baccarini P, Fiorentino M, D'Errico A, et al. Detection of antisense transcripts of the insulin-like growth factor-2 gene in Wilms' tumor. Am J Pathol 1993; 143: 1535-1542.
31. Krystal GW, Armstrong BC, Battey JF. N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts. Mol Cell Biol 1990; 10: 4180-4191.
32. Savage MP, Fallon JF. FGF-2 mRNA and its antisense message are expressed in a developmentally specific manner in the chick limb bud and mesonephros. Dev Dyn 1995; 202: 343-353.
33. Nellen W, Lichtenstein C. What makes an mRNA anti-sense-tive? TIBS 1993; 18: 419-423.
34. Cuevas EC, Bateman AC, Wilkins BS, et al. Microwave antigen retrieval in immunocytochemistry: a study of 80 antibodies. J Clin Pathol 1994; 47: 448-452.
35. Dougherty WG, Parks TD. Transgenes and gene suppression: telling us something new?. Curr Opin Cell Biol 1995; 7: 399-405.
36. Bard JBL, McConnell JE, Davies JA. Towards a genetic basis for kidney development. Mech Dev 1994; 48: 3-11.
37. Farrell CM, Lukens LN. Naturally occurring antisense transcripts are present in chick embryo chondrocytes simultaneously with the down-regulalion of the al (I) collagen gene. J Biol Chem 1995; 270: 3400-3408.
38. Noguchi M, Miyamoto S, Silverman TA, et al. Characterization of an antisense Inr element in the eIF-2 alpha gene. J Biol Chem 1994; 249: 29161-29167.
39. Greenblatt J, Nodwell JR, Mason SW. Transcriptional antitermination (Review), Nature 1993; 364: 401-406.